Fungal Infections in the ICU

Infectious Disease Clinics of North America

Volumn 23, Issue 3, 2009, Pages 625-642

  Zilberberg, Marya D ^a,b   Shorr, Andrew F ^c,d  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b EviMed Research Group LLC   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspergillus; Candida; Critical illness; Fungal infection; ICU; Invasive

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; BLOODSTREAM INFECTION; BRONCHOPULMONARY ASPERGILLOMA; BRONCHOSCOPY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CANDIDIASIS; CATHETER REMOVAL; CLINICAL FEATURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL COLONIZATION; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; LUNG SURGERY; MYCOSIS; NAUSEA; NEPHROTOXICITY; REVIEW; RISK FACTOR; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; VOMITING;

CANDIDIASIS; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS; PULMONARY ASPERGILLOSIS;

EID: 68249120323     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.04.008     Document Type: Review

References (83)

1. Groll A.H., Shah P.M., Mentzel C., et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
2. Paterson D.L., and Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 78 (1999) 123-138
3. Samarakoon P., and Soubani A.O. Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature. Chron Respir Dis 5 (2008) 19-27
4. Vandewoude K., Blot S., Benoit D., et al. Invasive aspergillosis in critically ill patients: analysis of risk factors fro acquisition and mortality. Acta Clin Belg 59 (2004) 251-257
5. Vandewoude K.H., Blot S.I., Benoit D., et al. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 56 (2004) 269-276
6. Meersseman W., Vandecasteele S.J., Wilmer A., et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170 (2004) 621-625
7. Vandewoude K.H., Blot S.I., Depuydt P., et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 10 (2006) 31
8. Buckingham S.J., and Hansell D.M. Aspergillus in the lung: diverse and coincident forms. Eur Radiol 13 (2003) 1786-1800
9. Maertens J., Verhaegen J., Lagrou K., et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97 (2001) 1604-1610
10. Sulahian A., Tabouret M., Ribaud P., et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of aspergillosis. Eur J Clin Microbiol Infect Dis 15 (1996) 139-145
11. Swanink C.M., Meis J.F., Rijs A.J., et al. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 35 (1997) 257-260
12. Pfeiffer C.D., Fine J.P., and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42 (2006) 1417-1427
13. Herbrecht R., Letscher-Bru V., Oprea C., et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20 (2002) 1898-1906
14. Pinel C., Fricker-Hidalgo H., Lebeau B., et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 41 (2003) 2184-2186
15. Husain S., Paterson D.L., Studer S.M., et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 83 (2007) 1330-1336
16. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
17. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
18. Hope W.W., Billaud E.M., Lestner J., et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 21 (2008) 580-586
19. Bowden R., Chandrasekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35 (2002) 359-366
20. Leenders A.C., Daenen S., Jansen R.L.H., et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103 (1998) 205-212
21. Cornley O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44 (2007) 1289-1297
22. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
23. Caillot D., Bassaris H., McGeer A., et al. Intravenous itraconazole followed by oral itraconazole I. The treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33 (2001) e83-e90
24. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 79 (2000) 250-260
25. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
26. Denning D.W., Marr K.A., Lau W.M., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53 (2006) 337-349
27. Kontoyiannis D.P., Ratanatharathorn V., Young J.A., et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 11 (2009) 89-93
28. Marr K.A., Boeckh M., Carter R.A., et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
29. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 15 (2006) 320-326
30. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20 (2007) 133-163
31. Hidron A.I., Edwards J.R., Patel J., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29 (2008) 996-1011
32. Banerjee S.N., Emori T.G., and Culver D.H. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 91 (1991) 86S-89S
33. Fridkin S.K., Kaufman D., Edwards J.R., et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 117 (2006) 1680-1687
34. San Miguel L.G., Cobo J., Otheo E., et al. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 26 (2005) 548-552
35. Trick W.E., Fridkin S.K., Edwards J.R., et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35 (2002) 627-630
36. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
37. Shorr AF, Shorr AF, Tabak YP, et al. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large US database. Crit Care Med, in press.
38. Zilberberg M.D., Shorr A.F., and Kollef M.H. Secular trends in candidemia-related hospitalizations in the US, 2000-2005. Infect Control Hosp Epidemiol 29 (2008) 978-980
39. Sandven P., Bevanger L., Digranes A., et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44 (2006) 1977-1981
40. Poikonen E., Lyytikamen O., Anttila V.J., et al. Canididemia in Finland, 1995-1999. Emerg Infect Dis 9 (2003) 985-990
41. Smith P.B., Morgan J., Benjamin J.D., et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J 26 (2007) 197-200
42. Zaoutis T.E., Argon J., Chu J., et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41 (2005) 1232-1239
43. Snydman D.R. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 123 (2003) 500-503
44. Nguyen M.H., Peacock Jr. J.E., Morris A.J., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100 (1996) 617-623
45. Bassetti M., Righi E., Costa A., et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6 (2006) 21
46. Shorr A.F., Lazarus D.R., Sherner J.H., et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 35 (2007) 1077-1083
47. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45 (2007) 1735-1745
48. Wey S.B., Mori M., Pfaller M.A., et al. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 149 (1989) 2349-2353
49. Pittet D., Monod M., Suter P.M., et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220 (1994) 751-758
50. Fraser V.J., Jones M., Dunkel J., et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15 (1992) 414-421
51. Blumberg H.M., Jarvis W.R., Soucie J.M., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33 (2001) 177-186
52. Chow J.K., Golan Y., Ruthazer R., et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 36 (2008) 1993-1998
53. Leon C., Ruiz-Santana S., Saavedra P., et al. A bedside scoring system (Candida score) for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization. Crit Care Med 34 (2006) 730-737
54. Ostrosky-Zeichner L., Sable C., Sobel J., et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26 (2007) 271-276
55. Faiz S., Neale B., Rios E., et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis (2008) in press
56. Reiss E., and Morrison C.J. Nonculture methods for diagnosis of disseminated candidiasis. Clin Microbiol Rev 6 (1993) 311-323
57. Mean M., Marchetti O., and Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 12 (2008) 204
58. Garbino J., Lew D.P., Romand J.A., et al. Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 28 (2002) 1708-1717
59. Eggimann P., Francioli P., Bille J., et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27 (1999) 1066-1072
60. Shorr A.F., Chung K., Jackson W.L., et al. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 33 (2005) 1928-1935
61. Nolla-Salas J., Sitges-Serra A., Leon-Gil C., et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 23 (1997) 23-30
62. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents Chemother 49 (2005) 3640-3645
63. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006) 25-31
64. Labelle A.J., Micek S.T., Roubinian N., et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 36 (2008) 2967-2972
65. Shuster M.G., Edwards J.E., Sobel J.D., et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149 (2008) 83-90
66. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
67. Nucci M., Colombo A.L., Silveira F., et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 19 (1998) 846-850
68. Pasqualotto A.C., de Moraes A.B., Zanini R.R., et al. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 28 (2007) 799-804
69. Walsh T.J., and Rex J.H. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 34 (2002) 600-602
70. Rodriguez D., Park B.J., Almirante B., et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 13 (2007) 788-793
71. Pasqualotto A.C., and Severo L.C. The importance of central venous catheter removal in patients with candidaemia: time to rethink our practice?. Clin Microbiol Infect 14 (2008) 2-4
72. Raad I., Hanna H., Boktour M., et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 38 (2004) 1119-1127
73. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 (1999) 764-771
74. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331 (1994) 1325-1330
75. Phillips P., Shafran S., Garber G., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 16 (1997) 337-345
76. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised noninferiority trial. Lancet 366 (2005) 1435-1442
77. Caspofungin prescribing information. Available at:. http://www.merck.com/product/usa/pi_circulars/c/cancidas/cancidas_pi.pdf Accessed January 18, 2009
78. Anidulafungin prescribing information. Available at:. http://media.pfizer.com/files/products/uspi_eraxis.pdf Accessed January 18, 2009
79. Micafungin prescribing information. Available at:. http://www.astellas.us/docs/mycamine-ic.xml Accessed January 18, 2009
80. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
81. Kuse E.R., Chetchotosakd P., da Cunha C.A., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
82. Pappas P.G., Rotstein C.M., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
83. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482